A MULTICENTER, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CEFTAROLINE FOSAMIL VERSUS CEFTRIAXONE PLUS VANCOMYCIN IN ADULT SUBJECTS WITH COMMUNITY ACQUIRED B

Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus

Approval Date: 10/19/2012

Principal Investigator: Matthew D. Sims, MD PhD

The purpose of this study is to determine whether ceftaroline is effective and safe for the treatment of patients with Community-acquired Bacterial Pneumonia (CABP) at risk for infection due to Methicillin-resistant Staphylococcus aureus (MRSA).

Eligibility:

Every study has inclusion and exclusion criteria that determine who is able to participate in the study. The study PI will evaluate if you meet these criteria. More information may be found here on clinicaltrials.gov.

Contact Person:
Myrene Bette
248-995-6869

Status of Clinical Trial:
open and enrolling